AERI stock forecast
Our latest prediction for Aerie Pharmaceuticals, Inc.'s stock price was made on the Sept. 9, 2019 when the stock price was at 20.47$.
In the short term (2weeks), AERI's stock price should outperform the market by 3.54%. During that period the price should oscillate between -8.71% and +12.16%.
In the medium term (3months), AERI's stock price should outperform the market by 1.50%. During that period the price should oscillate between -21.17% and +29.59%.Get email alerts
About Aerie Pharmaceuticals, Inc.
Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.
At the moment the company generates 48M USD in revenues.
On its last earning announcement, the company reported a loss of -5.22$ per share.
The book value per share is 4.30$
Three months stock forecastSept. 9, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|